Novo Nordisk shares slide after guidance disappoints investors
Summary
Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.
Visit the original source for the full article
📖 Read article in English
💼 Related articles — Finance & Business
Phillies Get Field Of Dreams Game Update After MLB Rule Change
Disney’s next streaming bet depends on creators. Will it pay them?
Iconic Blue Jays Voice Addresses Viral Health Concerns
Meet 21 Black women who bounced back and are thriving after being pushed out of the workplace
Why Jennifer Garner Is Doubling Down On Her Organic Kids’ Food Brand
Celebrating the 90th birthday of the Wienermobile, the original marketing stunt
Trump Backs FIFA Boss Infantino Amid Growing Revolt By Soccer Nations
💼
You can see both a partial solar eclipse and the Perseid meteor shower peak on the same day this week. Here’s when to look up
New Kawhi Leonard Cap-Circumvention Allegations Raise The Stakes For The NBA
The design world is already obsessed with this recommendation app. Now, you will be too
College Football Playoff Format Slightly Changes In 2026 As Expansion Remains Possible
BDG CEO Bryan Goldberg’s plan for media after the pageview
4 Reasons For Jeff Bezos To Be Bullish On Liverpool FC
Tech Mass Layoffs Are Creating a Once-In-a-Lifetime Opportunity for Small Business Growth
Behind AI Investment, U.S. Trade Deficit Grows 4th Consecutive Month
To save $30 million, LAX built its new concourse outside the airport